Impact of COVID-19 on Economy, Industry and Company :
The emergence of novel coronavirus has affected the global economy, industry dynamics and company’s top line. The entire ecosystem has to suffer the impact of this pandemic disease which would result in significant demand & supply gap, production delay and weak consumer demand of end products across industries. At Bizizz Market Research, our analyst has done extensive research across industries and identify various methodologies which would assist C-Level executive to counter this ongoing threat and make informed business decision.
Kindly contact us to know more details: https://www.bizizzmarketresearch.com/contact
Global Short Bowel Syndrome Market was Valued at US$ XX Bn in 2019 and it is Expected to Reach More than US$ 6.2 Bn by 2028, Likely to Grow with the CAGR of 27.1% During the Forecast Period.
Short bowel syndrome can be defined as a type of complex disease which is the result of the undernourishment of a portion of large of the small intestine. The patients of short bowel syndrome show poor intake of nutrients such as minerals, water, vitamins, carbohydrates, or fats, which result in weight loss or malnutrition. The global short bowel syndrome market is at its initial phase and expected to show robust growth in the future. Some of the major factors driving the growth of global short bowel syndrome include increasing availability of epidemiological data, the evolution of the healthcare industry, and government initiative taken for the manufacture of drugs for the treatment of short bowel syndrome.
Government and NGO’s Initiatives have Led to the Growth of the Short Bowel Syndrome Market
The global short bowel syndrome is majorly driven by NGO’s initiatives coupled with government funding and approval for these drugs. The non-profit organizations are highly engaged in the promotion of R&D activities for the development of short bowel syndrome treatment among private and public sectors. Also, the regional government offer incentive for the production of these drugs, which encourages pharmaceutical companies to expand their operations in this sector. Also, the growing healthcare and pharmaceutical industry are expected to create growth opportunities for short bowel syndrome market.
However, lack of awareness and limited approved treatments might hamper the growth of the global short bowel syndrome market.
Glucagon-like Peptide-2 (GLP-2) Segment is the Fastest Growing Segment in the Global Short Bowel Syndrome Market
Based on drug class, the glucagon-like peptide is anticipated to show immersive growth, registering for the highest CAGR over the forecast period. Revestive/Gattex is the only available glucagon-like peptide treatment for short bowel syndrome. The surgeons are highly recommending GLP-2 treatment. Though, currently, the drug is commercially available in very limited regions including some countries of Europe and North America. Still, the segment is expected to expand its sales worldwide. Moreover, the higher cost of other drugs is favoring the growth of the GLP-2 segment in the future.
The other drugs used in the treatment for short bowel syndrome is anticipated to show moderate growth during the forecast period. The other drugs include Zorbtive, NutreStore, proton pump inhibitors, and include anti-diarrheal.
North America Occupied Highest Market Share whereas the Asia Pacific is Showing Impressive Growth
In terms of region, North America is anticipated to dominate the global short bowel syndrome market over the forecast period. On the other hand, Asia Pacific is expected to grow at the fastest compound annual growth rate during the forecast period. Furthermore, Europe is the second-largest contributor to the global market.
In North America, the U.S. is the major contributor to the global short bowel syndrome market. The growth of North America can be attributed to the presence of major players operating in the market in the region. The companies are engaged in promotional activities intended to increase awareness among consumers which is favoring the growth of the market in North America.
Continuous Research to Achieve Perfect Sensitivity is the Strategy Adopted by the Players Present in this Market
The global Short Bowel Syndrome market is consolidated with a few global players. In the global Short Bowel Syndrome market, 4-5 companies hold more than 80 % of the market share. The companies are focused on research and development activities to develop innovative products and also add some value to their existing portfolio. This strategy is intended to strengthen its foothold in the global market. For instance, in May 2019 Takeda Pharmaceuticals, U.S.A., Inc. announced the approval of FDA for GATTEX. The drug is used for 1 year or older patients suffering from short bowel syndrome and need additional fluid and nutrition from the mother’s feeding.
Some of the prominent companies operating in global Short Bowel Syndrome market include Naia Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, Pfizer Inc., Sancilio & Company, Inc., Emmaus Life Sciences, Inc., OxThera, Ardelyx, Inc., and Nutrinia Ltd.
Global Short Bowel Syndrome Market by Drug Class
- Glucagon-like Peptide-2 (GLP-2)
- Growth Hormone
Global Short Bowel Syndrome Market by Region
- North America
- Latin America
- Asia Pacific
- Middle East & Africa